Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

204
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
204
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

352
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
352
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

324
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
324
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

445
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
445

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.

Infection and drug resistance·2026
Same author

Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.

Emerging infectious diseases·2026
Same author

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial.

The lancet. HIV·2025
Same author

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.

Contemporary clinical trials·2025
Same author

A clinical practice guideline for tuberculous meningitis.

The Lancet. Infectious diseases·2025
Same journal

THE GORDON WILSON MEMORIAL LECTURE.

Transactions of the American Clinical and Climatological Association·2025
Same journal

HEALTHY AGING: THE PROMISE, AND PERILS, OF GEROSCIENCE.

Transactions of the American Clinical and Climatological Association·2025
Same journal

TESTOSTERONE AND INSULIN RESISTANCE IN MEN: EVIDENCE FOR A COMPLEX BI-DIRECTIONAL RELATIONSHIP.

Transactions of the American Clinical and Climatological Association·2025
Same journal

REVISITING GLUCAGON ACTION IN DIABETES: IS IT ALL BAD?

Transactions of the American Clinical and Climatological Association·2025
Same journal

DECEASED MEMBERS 1884 THROUGH 2024.

Transactions of the American Clinical and Climatological Association·2025
Same journal

OFFICERS AND COUNCIL FALL 2025.

Transactions of the American Clinical and Climatological Association·2025
查看所有相关文章

相关实验视频

Updated: Sep 12, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

彻底改变结核病的发展模式

Kelly E Dooley1, Radojka Savic1

  • 1Nashville, TN.

Transactions of the American Clinical and Climatological Association
|August 7, 2025
PubMed
概括
此摘要是机器生成的。

数据整合和计算方法方面的创新正在加速结核病药物开发. 这一进展旨在更快地提供新的治疗方法,以打击耐药结核病日益增长的威胁.

更多相关视频

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

相关实验视频

Last Updated: Sep 12, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

科学领域:

  • 药物发现和开发 药物发现和开发
  • 计算生物学 计算生物学
  • 传染性疾病 传染性疾病

背景情况:

  • 在20世纪50年代至70年代之间建立的第一线结核病 (TB) 治疗方法面临停滞,最近的药物批准是在漫长的开发周期和高失败率之后获得的.
  • 结核病药物开发管道目前是强大的,具有多种新的化学实体,需要优化进步战略.
  • 对现有结核病药物的新兴耐药性强调了对新型治疗剂的迫切需要.

研究的目的:

  • 探索数据集成和计算方法的最新创新如何可以彻底改变结核病药物开发.
  • 加速开发时间表,增加新的结核病化合物的成功概率.
  • 促进新型药物的及时批准,以应对全球结核病流行病.

主要方法:

  • 利用最近数据整合技术的进步.
  • 在药物发现和开发过程中应用创新的计算方法.
  • 分析结核病药物开发管道,以优化机会.

主要成果:

  • 最近的创新被认为是彻底改变结核病药物开发的关键驱动力.
  • 预计加速开发时间表和更高的成功概率.
  • 新型结核病药物的前所未有的批准时间框架的潜力.

结论:

  • 数据整合和计算方法为优化结核病药物开发提供了强大的策略.
  • 这些进展有望更有效地提供新的结核病药物,解决耐药性的挑战.
  • 探索的策略对其他医学领域的药物开发具有潜在的适用性.